Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Independence Blue CrossMedicare Advantage · Documentation · Pharmacy · Oncology, PharmacyMedium impact

MA08.129b, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (Phesgo®)

Act
by Nov 17, 2025
Effective date
Nov 17, 2025
Identified
Jun 19, 2026

Summary

Independence Blue Cross updated Medicare Advantage policy MA08.129b effective 11/17/2025 to align with FDA labeling and NCCN guidelines for Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf). All ICD-10 diagnosis codes were removed from the policy attachment; billing teams must now report the most appropriate diagnosis code from their standard coding references to support medical necessity rather than using a pre-defined code list.

Get alerts when payers change rules like this one

We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.

Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.

What to do

by Nov 17, 2025 · 6 steps
01Billing team must update claim submission procedures for HCPCS code J9316 (Phesgo).
02Remove reliance on any attached ICD-10 code list from the previous policy version.
03Implement new workflow: providers must document one of the four covered clinical scenarios (neoadjuvant treatment, adjuvant treatment, metastatic treatment with docetaxel, or IV substitute) AND include HER2 testing confirmation (IHC 3+, FISH positive, or ISH positive) AND document LVEF >55% (or >50% for metastatic cases).
04Billing team must select and report the most clinically appropriate ICD-10 diagnosis code from standard coding resources that matches the documented clinical indication.
05Update claim validation rules to require evidence of HER2 testing and LVEF documentation before processing.
06Flag any claims without these supporting documents for denial or request for additional information.

Codes mentioned

J9316

Original notice

MA08.129b, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (Phesgo®)
medpolicy.ibx.com · Always check the source before changing claims.
View original ↗

Related changes

See all Independence Blue Cross changes →
MA08.129c, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (Phesgo®)MediumEffective Nov 2, 2026 · Pharmacy08.01.72c, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (Phesgo®)MediumEffective Nov 2, 2026 · Pharmacy08.01.72b, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (Phesgo®)MediumEffective Nov 17, 2025 · PharmacyBrowse every Independence Blue Cross change in the policy list

Related policy hubs

Independence Blue Cross policiesOncologyPharmacyCode J9316

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account